BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 34875337)

  • 1. Phosphodiesterase (PDE) 5 inhibitors sildenafil, tadalafil and vardenafil impact cAMP-specific PDE8 isoforms-linked second messengers and steroid production in a mouse Leydig tumor cell line.
    Limoncella S; Lazzaretti C; Paradiso E; D'Alessandro S; Barbagallo F; Pacifico S; Guerrini R; Tagliavini S; Trenti T; Santi D; Simoni M; Sola M; Di Rocco G; Casarini L
    Mol Cell Endocrinol; 2022 Feb; 542():111527. PubMed ID: 34875337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential effects of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, and tadalafil in rat aorta.
    Teixeira CE; Priviero FB; Webb RC
    J Pharmacol Exp Ther; 2006 Feb; 316(2):654-61. PubMed ID: 16204472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of the phosphodiesterase 5 inhibitors sildenafil, tadalafil and vardenafil on rat anococcygeus muscle: functional and biochemical aspects.
    Toque HA; Priviero FB; Zemse SM; Antunes E; Teixeira CE; Webb RC
    Clin Exp Pharmacol Physiol; 2009 Apr; 36(4):358-66. PubMed ID: 18986324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphodiesterase-5 Gln817 is critical for cGMP, vardenafil, or sildenafil affinity: its orientation impacts cGMP but not cAMP affinity.
    Zoraghi R; Corbin JD; Francis SH
    J Biol Chem; 2006 Mar; 281(9):5553-8. PubMed ID: 16407275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nebivolol potentiates the efficacy of PDE5 inhibitors to relax corpus cavernosum and penile arteries from diabetic patients by enhancing the NO/cGMP pathway.
    Martínez-Salamanca JI; La Fuente JM; Cardoso J; Fernández A; Cuevas P; Wright HM; Angulo J
    J Sex Med; 2014 May; 11(5):1182-92. PubMed ID: 24877179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro effects of PDE5 inhibitors sildenafil, vardenafil and tadalafil on isolated human ureteral smooth muscle: a basic research approach.
    Gratzke C; Uckert S; Kedia G; Reich O; Schlenker B; Seitz M; Becker AJ; Stief CG
    Urol Res; 2007 Feb; 35(1):49-54. PubMed ID: 17102958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation.
    Blount MA; Beasley A; Zoraghi R; Sekhar KR; Bessay EP; Francis SH; Corbin JD
    Mol Pharmacol; 2004 Jul; 66(1):144-52. PubMed ID: 15213306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphodiesterase type 5 inhibitors facilitate noncontact erections in male rats: site of action in the brain and mechanism of action.
    Sanna F; Succu S; Boi A; Melis MR; Argiolas A
    J Sex Med; 2009 Oct; 6(10):2680-9. PubMed ID: 19678884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy of tadalafil once daily in men with erectile dysfunction who demonstrated previous partial responses to as-needed sildenafil, tadalafil, or vardenafil.
    Kim E; Seftel A; Goldfischer E; Baygani S; Burns P
    Curr Med Res Opin; 2015 Feb; 31(2):379-89. PubMed ID: 25455432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil.
    Saenz de Tejada I; Angulo J; Cuevas P; Fernández A; Moncada I; Allona A; Lledó E; Körschen HG; Niewöhner U; Haning H; Pages E; Bischoff E
    Int J Impot Res; 2001 Oct; 13(5):282-90. PubMed ID: 11890515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PDE5 inhibitors, sildenafil and vardenafil, reverse multidrug resistance by inhibiting the efflux function of multidrug resistance protein 7 (ATP-binding Cassette C10) transporter.
    Chen JJ; Sun YL; Tiwari AK; Xiao ZJ; Sodani K; Yang DH; Vispute SG; Jiang WQ; Chen SD; Chen ZS
    Cancer Sci; 2012 Aug; 103(8):1531-7. PubMed ID: 22578167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exposure to phosphodiesterase type 5 inhibitors stimulates aromatase expression in human adipocytes in vitro.
    Aversa A; Caprio M; Antelmi A; Armani A; Brama M; Greco EA; Francomano D; Calanchini M; Spera G; Di Luigi L; Rosano GM; Lenzi A; Migliaccio S; Fabbri A
    J Sex Med; 2011 Mar; 8(3):696-704. PubMed ID: 21176111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The ENDOTRIAL study: a spontaneous, open-label, randomized, multicenter, crossover study on the efficacy of sildenafil, tadalafil, and vardenafil in the treatment of erectile dysfunction.
    Jannini EA; Isidori AM; Gravina GL; Aversa A; Balercia G; Bocchio M; Boscaro M; Carani C; Corona G; Fabbri A; Foresta C; Forti G; Francavilla S; Granata AR; Maggi M; Mansani R; Palego P; Spera G; Vetri M; Lenzi A;
    J Sex Med; 2009 Sep; 6(9):2547-60. PubMed ID: 19570039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of high affinity ATP-dependent cyclic nucleotide transporters by specific and non-specific cyclic nucleotide phosphodiesterase inhibitors.
    Aronsen L; Orvoll E; Lysaa R; Ravna AW; Sager G
    Eur J Pharmacol; 2014 Dec; 745():249-53. PubMed ID: 25445042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells.
    Sarfati M; Mateo V; Baudet S; Rubio M; Fernandez C; Davi F; Binet JL; Delic J; Merle-Beral H
    Blood; 2003 Jan; 101(1):265-9. PubMed ID: 12393651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Testosterone/estradiol ratio regulates NO-induced bladder relaxation and responsiveness to PDE5 inhibitors.
    Vignozzi L; Filippi S; Morelli A; Comeglio P; Cellai I; Sarchielli E; Maneschi E; Mancina R; Gacci M; Vannelli GB; Maggi M
    J Sex Med; 2012 Dec; 9(12):3028-40. PubMed ID: 23057807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sildenafil treatment in vivo stimulates Leydig cell steroidogenesis via the cAMP/cGMP signaling pathway.
    Andric SA; Janjic MM; Stojkov NJ; Kostic TS
    Am J Physiol Endocrinol Metab; 2010 Oct; 299(4):E544-50. PubMed ID: 20663985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphodiesterase 5 inhibitors in male sexual dysfunction.
    Kuthe A
    Curr Opin Urol; 2003 Sep; 13(5):405-10. PubMed ID: 12917517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of phosphodiesterases in the urogenital system: new directions for therapeutic intervention.
    Montorsi F; Corbin J; Phillips S
    J Sex Med; 2004 Nov; 1(3):322-36. PubMed ID: 16422964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphodiesterase-5 isoforms: differential cyclic guanyl monophosphate binding and cyclic guanyl monophosphate catalytic activities, and inhibitory effects of sildenafil and vardenafil.
    Lin G; Xin ZC; Lue TF; Lin CS
    J Urol; 2006 Sep; 176(3):1242-7. PubMed ID: 16890733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.